Games developer tinyBuild seeks to boost £500 million market cap by becoming a media company. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImmupharma Share News (IMM)

Share Price Information for Immupharma (IMM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 8.78
Bid: 8.34
Ask: 8.78
Change: 0.00 (0.00%)
Spread: 0.44 (5.28%)
Open: 8.20
High: 8.88
Low: 8.18
Yest. Close: 8.40
IMM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

AIM WINNERS & LOSERS: Tavistock Rises As Tips Annual Earnings Climb

Tue, 9th Feb 2021 10:42

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.



AIM - WINNERS



Tavistock Investments, up 20% at 2.28 pence, 12-month range 1.00p-2.40p. The Bracknell-based fund manager says its financial performance during the pandemic has been "resilient", and it expects to report full-year earnings growth. Tavistock expects earnings before interest, tax, depreciation and amortisation for the financial year to March 31 to be "significantly ahead" of last year.



Pressure Technologies, up 14% at 100.02 pence, 12-month range 50.10p-147.00p. Its subsidiary Chesterfield Special Cylinders secures a contract with Haskel Hydrogen Group for the supply of high-pressure type-one steel vessels. The vessels will be used for hydrogen storage in three new hydrogen refuelling stations.



Joules Group, up 6.3% at 170.00 pence, 12-month range 32.80p-188.00p. The retailer buys Garden Trading Co for up to GBP12.5 million. The consideration will comprise an upfront payment of GBP9 million, of which GBP4.5 million will be paid in cash and the remainder in 2.8 million Joules shares. The deferred consideration is for up to GBP3.5 million, of which at least GBP3 million will be paid in cash and the rest either in cash or shares. Garden Trading is a home and garden products retailer.



Alba Mineral Resources, up 9.0% at 0.39 pence, 12-month range 0.040p-0.580p. Reports on testwork at its Amitsoq graphite asset in Greenland. Results confirm that graphite content at the project "is very high, amongst the highest found in flake graphite deposits globally".



AIM - LOSERS



Immupharma, down 14% at 10.15p, 12-month range 7.01p-21.39p. The London-based pharmaceutical development company says it has received feedback from the US health regulators regarding plans for a phase three trial of Lupus treatment Lupuzor. Immupharma noted a US Food & Drug Administration special protocol assessment will not be applicable and a conditional approval of Lupuzor, "has not been confirmed at this time". An FDA special protocol assessment refers to when a trial's clinical endpoints and design are approved. Immupharma adds it is on track to begin the phase 3 study in the second half of 2021.



By Eric Cunha; ericcunha@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News

EXECUTIVE CHANGES: Gresham House Strategic plots future as chair exits

EXECUTIVE CHANGES: Gresham House Strategic plots future as chair exits

24 May 21 15:32

TRADING UPDATES: Keystone Law and Checkit post annual revenue growth

TRADING UPDATES: Keystone Law and Checkit post annual revenue growth

29 Apr 21 17:33

ImmuPharma clarifies next steps for phase 3 Lupuzor trial

(Sharecast News) - Specialist drug discovery and development company ImmuPharma updated the market on the new optimised international phase 3 trial of 'Lupuzor' in the potentially life-threatening auto-immune disease systemic lupus erythematosus (SLE) on Tuesday.

9 Feb 21 14:13

AIM WINNERS & LOSERS: Tavistock Rises As Tips Annual Earnings Climb

AIM WINNERS & LOSERS: Tavistock Rises As Tips Annual Earnings Climb

9 Feb 21 10:42

No Conditional US Approval So Far For ImmuPharma Lupus Drug Lupuzor

No Conditional US Approval So Far For ImmuPharma Lupus Drug Lupuzor

9 Feb 21 10:36

UK TRADING UPDATE SUMMARY: Gore Street Energy Energises Drumkee

UK TRADING UPDATE SUMMARY: Gore Street Energy Energises Drumkee

24 Nov 20 21:30

IN BRIEF: Immupharma Says L1 Capital Converts USD200,000 Of Security

IN BRIEF: Immupharma Says L1 Capital Converts USD200,000 Of Security

23 Nov 20 14:29

ImmuPharma gets December date for FDA meeting

(Sharecast News) - Specialist drug discovery and development company ImmuPharma updated the market on the new optimised international phase 3 trial of 'Lupuzor' in systemic lupus erythematosus (SLE) on Friday, reporting that the US Food & Drug Administration (FDA) has now confirmed the date of 4 December for a Type 'A' Meeting Request.

20 Nov 20 12:15

ImmuPharma Partner To Discuss Progression Of Lupuzor Drug With US FDA

ImmuPharma Partner To Discuss Progression Of Lupuzor Drug With US FDA

20 Nov 20 11:04

UK TRADING UPDATE SUMMARY: Newly-Listed Wheaton Reports Bumper Quarter

UK TRADING UPDATE SUMMARY: Newly-Listed Wheaton Reports Bumper Quarter

10 Nov 20 17:40

UK EARNINGS SUMMARY: Itaconix 2019 Loss Narrows On Strong Revenue Rise

UK EARNINGS SUMMARY: Itaconix 2019 Loss Narrows On Strong Revenue Rise

30 Sep 20 18:37

IN BRIEF: Immupharma Raises Stake In Incanthera To 15.4%

IN BRIEF: Immupharma Raises Stake In Incanthera To 15.4%

29 Sep 20 18:19

IN BRIEF: Immupharma Repays Lind Global Convertible Security

IN BRIEF: Immupharma Repays Lind Global Convertible Security

22 Sep 20 21:17

IN BRIEF: Immupharma Still Awaiting FDA Reply For Lupuzor Submission

IN BRIEF: Immupharma Still Awaiting FDA Reply For Lupuzor Submission

11 Sep 20 14:09

ImmuPharma confirms continued FDA delays for Lupuzor

(Sharecast News) - Specialist drug discovery and development company ImmuPharma on its special protocol assessment (SPA) submission to the US Food and Drug Administration (FDA) for the phase 3 trial of 'Lupuzor' in lupus patients.

11 Sep 20 12:17

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.